Status:
RECRUITING
Dexmedetomidine, Ozone and Dexamethasone Local Injection in Carpal Tunnel Syndrome for Pain Relief
Lead Sponsor:
Tanta University
Conditions:
Carpal Tunnel
Dexmedetomidine
Eligibility:
All Genders
20-60 years
Phase:
NA
Brief Summary
The aim of the present study is to compare the analgesic efficacy of Dexmedetomidine, Ozone and Dexamethasone regional injection in carpal tunnel syndrome.
Detailed Description
Carpal tunnel syndrome (CTS) is a collection of symptoms and signs associated with median neuropathy at the carpal tunnel. Most CTS is related to idiopathic compression of the median nerve as it trave...
Eligibility Criteria
Inclusion
- Age from 20 to 60 years.
- Both sexes.
- Patients with ultrasonographic evidence of mild-to-moderate carpal tunnel syndrome (CTS).
- Inclusion criteria will include numbness and pain in the median nerve (MN) distribution persisting for minimum of 3 months , nerve conduction studies (NCS) consistent with carpal tunnel syndrome (CTS) as per the American Association of Neuromuscular and Electro diagnostic Medicine (AANEM) guidelines, and an median nerve (MN) cross-sectional area (CSA)at the wrist \>12 mm2 suggesting mild-to-moderate CTS forms.
Exclusion
- Patient refusal.
- Patients with severe symptoms and signs of CTS as identified per the American Association of Neuromuscular and Electro diagnostic Medicine (AANEM) guidelines,\[14\] as this is an indication for surgery,
- Patients who show improvement on medical treatment,
- Previous surgical or injectional CTS treatment,
- Pregnancy ,co existence of brachial plexopathy, or thoracic outlet syndrome, polyneuropathy, radiculopathy and peripheral nerve lesion in upper limb.
- Severe cardiovascular disease
- Morbid obese patients (body mass index (BMI) of \>35 kg/m2)
- Infection at site of injection.
- Bleeding diathesis.
- History of thyroid deficiency, uncontrolled diabetes mellitus , rheumatoid arthritis and history of glucose-6-phosphate dehydrogenase (G6PD) deficiency
- History of Ozone or Dexmedetomidine allergy.
- End stage renal and hepatic disease.
- History of inflammatory joint , connective tissue disorders, , burns, any local tissue contractures and history of wrist trauma.
- Patients who will not consent to completing The visual analogue scale (VAS) for pain or nerve conduction study before and after injection.
Key Trial Info
Start Date :
November 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
135 Patients enrolled
Trial Details
Trial ID
NCT06133712
Start Date
November 1 2023
End Date
December 1 2025
Last Update
May 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Medicine
Tanta, El Gharbia, Egypt, 31527